Bronchodilators in heart failure patients with COPD: is it time for a clinical trial?

Journal of Cardiac Failure
Robert J MentzChristopher M O'Connor

Abstract

Chronic heart failure (HF) and chronic obstructive pulmonary disease (COPD) commonly coexist, and patients with both diseases fare worse than those with either disease alone. Several factors may contribute to worse outcomes, including an increased burden of care related to greater disease complexity, an overlap of symptoms resulting in misapplication of therapy, and the adverse effects of treatment for one disease on the symptoms and outcomes related to the other. For example, there are conflicting data about the cardiovascular risks of bronchodilators in HF patients who may experience worse outcomes with inhaled beta-2 agonists via arrhythmogenesis, ischemia, and/or attenuation of beta-blocker benefits. In contrast, the long-acting anticholinergic class of bronchodilators has a more reassuring safety profile. Anticholinergic bronchodilators may be the preferred first-line agents for COPD patients with comorbid HF, yet data supporting these recommendations are limited. Therapeutic trials in COPD patients have generally excluded patients with significant HF and vice-versa. This paper reviews bronchodilator therapy in HF and proposes a randomized trial designed to enroll patients with significant COPD and HF to determine the risk...Continue Reading

References

Jun 1, 1992·The American Review of Respiratory Disease·C C NaumR M Rogers
Aug 10, 1989·The New England Journal of Medicine·UNKNOWN Cardiac Arrhythmia Suppression Trial (CAST) Investigators
Jan 1, 1982·British Journal of Clinical Pharmacology·R E RuffinJ H Alpers
Mar 1, 1983·Archives of Internal Medicine·R W Light, R B George
Dec 1, 1996·American Journal of Respiratory and Critical Care Medicine·S SuissaP Ernst
Feb 15, 2001·Current Cardiology Reports·G M Felker, C M O'Connor
Jan 29, 2002·European Journal of Heart Failure·Christopher T C LienMarion E T McMurdo
Jun 20, 2002·Journal of Cardiovascular Pharmacology·Tien M H NgRalph A Lugo
Aug 3, 2002·American Journal of Respiratory and Critical Care Medicine·Nicholas R AnthonisenUNKNOWN Lung Health Study Research Group
Mar 5, 2003·Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine·Peter A McCulloughUNKNOWN BNP Multinational Study Investigators
Oct 3, 2003·Journal of the American College of Cardiology·Joel B BraunsteinAlbert W Wu
Oct 21, 2004·The Annals of Pharmacotherapy·Alexander A FisherDarryl A McGill
Nov 4, 2004·American Heart Journal·David H AuUNKNOWN ACQUIP Investigators
Jan 12, 2005·European Journal of Heart Failure·Martje H L van der WalDirk J van Veldhuisen
Feb 5, 2005·Respirology : Official Journal of the Asian Pacific Society of Respirology·UNKNOWN Asia Pacific COPD Roundtable Group
Jun 16, 2005·QJM : Monthly Journal of the Association of Physicians·M EgredE Rodrigues
Oct 15, 2005·The Journal of International Medical Research·E BozkanatM Yokusoglu
Dec 15, 2006·Chest·Steven KestenStephan Lanes
Jan 16, 2007·Journal of the American College of Cardiology·Thierry H Le JemtelSanja Jelic
Feb 23, 2007·The New England Journal of Medicine·Peter M A CalverleyUNKNOWN TORCH investigators
Mar 8, 2007·European Journal of Epidemiology·Cynthia de LuiseHenrik T Sørensen
Oct 6, 2007·American Journal of Respiratory and Critical Care Medicine·Jadwiga A WedzichaUNKNOWN INSPIRE Investigators
Jan 29, 2008·International Journal of Cardiology·Margherita PadelettiThierry H LeJemtel
Jun 12, 2008·JAMA : the Journal of the American Medical Association·Norman C WangUNKNOWN Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators
Oct 7, 2008·The New England Journal of Medicine·Donald P TashkinUNKNOWN UPLIFT Study Investigators
Jan 27, 2009·European Journal of Heart Failure·Nathaniel Mark HawkinsJohn J V McMurray
Jul 14, 2009·Chest·Bartolome CelliDonald P Tashkin
Jul 29, 2009·Pulmonary Pharmacology & Therapeutics·E D BatemanI Wessler

❮ Previous
Next ❯

Citations

Mar 19, 2014·Respiratory Medicine·Luis Puente-MaestuUNKNOWN GEMEPOC Group
Aug 21, 2014·Expert Opinion on Investigational Drugs·Muhammad Ahsan ZafarRalph J Panos
Feb 3, 2016·Current Heart Failure Reports·Ingrid HopperThomas G von Lueder
Dec 3, 2014·Journal of the American College of Cardiology·Robert J MentzChristopher M O'Connor
Jul 3, 2013·Heart Failure Clinics·Robert J Mentz, G Michael Felker
Jan 1, 2013·Heart & Lung : the Journal of Critical Care·Armine G MinasianYvonne F Heijdra
Jun 21, 2015·International Journal of Cardiology·E SiniorakisE Rentoukas
Sep 4, 2013·Heart & Lung : the Journal of Critical Care·Armine G MinasianYvonne F Heijdra
Aug 21, 2016·International Journal of Cardiology·Wissam AlajajiGuilherme H Oliveira
Nov 7, 2016·Current Heart Failure Reports·Sergio Caravita, Jean-Luc Vachiéry
Nov 21, 2020·Journal of Medicinal Chemistry·Gang XingMao-Sheng Cheng
May 14, 2021·Circulation Research·Joyce N Njoroge, John R Teerlink

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.